Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

Eli Lilly and Company $LLY Shares Acquired by Elevation Point Wealth ...

AI-generated analysis

πŸ“ˆ Elevation Point Wealth Partners LLC increased its Eli Lilly stake by 106.2% in Q1, adding 21,749 shares to reach a total holding of 42,234 shares.

πŸ’° The institutional investor's position is valued at $38,846,000 and constitutes 0.9% of their total investment portfolio.

πŸ“Š Eli Lilly trades with a market cap of $1.14 trillion and a P/E ratio of 42.93 as of the latest filing data.

πŸ’΅ The company declared a quarterly dividend of $1.73 per share, resulting in an annualized yield of 0.6%.

πŸ“‰ HSBC downgraded Eli Lilly from 'hold' to 'reduce' and cut its price target from $1,070 to $850.

πŸ”Ό Jefferies Financial Group raised its price target to $1,350 and reiterated a 'buy' rating on the stock.

πŸ“Š Goldman Sachs maintains a 'buy' rating with a specific price objective of $1,283.00 for the shares.

πŸ›οΈ Approximately 82.53% of Eli Lilly's outstanding shares are currently owned by hedge funds and institutional investors.

πŸ“ˆ The stock has a beta of 0.51, indicating lower volatility relative to the broader market.

πŸ“… The ex-dividend date for the upcoming quarterly payout is set for Friday, August 14th.

Bullish Signals
  • Elevation Point Wealth Partners LLC significantly increased its position by 106.2% in Q1, signaling strong institutional confidence.
  • Multiple other hedge funds and institutions, including Sharp Wealth Advisory and Platform Technology Partners, also increased their stakes.
  • Major brokerages like Jefferies Financial Group and Goldman Sachs maintain 'buy' ratings with target prices above the current trading level.
  • The company maintains a healthy balance sheet with a quick ratio of 1.10 and a current ratio of 1.50.
  • Eli Lilly has established a consistent dividend history, recently declaring a $1.73 quarterly payment.
Risk Factors
  • HSBC downgraded the stock to a 'reduce' rating and lowered its price objective significantly to $850.
  • The high P/E ratio of 42.93 suggests the stock is trading at a premium valuation compared to historical averages.
  • Analyst consensus includes one 'Sell' rating and four 'Hold' ratings, indicating some market skepticism.
Full Analysis
Elevation Point Wealth Partners LLC significantly increased its stake in Eli Lilly and Company (NYSE: LLY) by 106.2% during the first quarter, purchasing an additional 21,749 shares to hold a total of 42,234 shares valued at approximately $38.8 million. This position represents 0.9% of Elevation Point's portfolio and ranks as its 16th largest holding. Several other institutional investors, including Sharp Wealth Advisory LLC, Platform Technology Partners, and Sound Income Strategies LLC, also increased their stakes in the pharmaceutical giant during the same period. The article details specific financial metrics for Eli Lilly, noting a market capitalization of $1.14 trillion and a current share price opening at $1,208.37. Key valuation ratios include a price-to-earnings ratio of 42.93 and a PEG ratio of 1.51. The company maintains a debt-to-equity ratio of 1.26 and has recently declared a quarterly dividend of $1.73 per share, payable on September 10th to shareholders of record on August 14th. Analyst sentiment remains mixed but generally positive, with major firms like Jefferies Financial Group and Goldman Sachs maintaining 'buy' ratings and target prices ranging from $1,283 to $1,350. However, HSBC recently downgraded the stock to a 'reduce' rating and lowered its price objective to $850. The consensus rating across MarketBeat is a 'Moderate Buy' with an average target price of $1,235.07, reflecting a diverse range of institutional opinions on the company's future performance.